Attruby Side Effects: What It Treats, How It Works, and What to Watch For

Attruby is a prescription medicine used for adults with transthyretin amyloid cardiomyopathy, a condition in which unstable transthyretin protein forms amyloid deposits that can affect the heart. Attruby side effects are often digestive, but patients should also understand liver monitoring, medication interactions, and symptoms that need prompt medical attention.

Overview: What are Attruby side effects?

Attruby side effects most commonly include diarrhea and upper abdominal pain. Some people may also have changes in liver blood-test results, so clinicians may consider liver-related monitoring based on the individual’s medical history and symptoms.

Attruby is the brand name for acoramidis. It is a prescription medicine approved in the United States for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive form of amyloidosis that affects the heart. It is intended to reduce cardiovascular death and cardiovascular-related hospitalizations in this condition.

Side effects should be considered in context. Diarrhea or abdominal discomfort can have many causes, including other medicines and diet, while breathlessness and swelling may be caused by the underlying heart condition. Patients should not stop Attruby on their own; a prescribing clinician can help determine whether symptoms are medicine-related and whether treatment should be adjusted.

What Attruby treats

ATTR-CM occurs when transthyretin (TTR), a protein made mainly in the liver, becomes unstable. The protein can separate and form amyloid fibrils, which accumulate in tissues. When deposits build up in the heart, the heart muscle may become stiff and less able to fill and pump effectively.

There are two broad forms of ATTR-CM. Wild-type ATTR-CM generally develops later in life without an inherited TTR gene change. Hereditary ATTR-CM is linked to a variant in the TTR gene and may affect several family members. A specialist evaluation can help establish the type and guide discussions about genetic counseling when appropriate.

Symptoms can overlap with other heart conditions and may include shortness of breath, fatigue, leg or ankle swelling, palpitations, dizziness, and reduced tolerance for activity. For more background on the condition, patients may find this information on cardiac amyloidosis helpful.

Attruby is not a cure for ATTR-CM, and it is not used to treat every kind of amyloidosis. It should be used as prescribed within a broader care plan that may include heart-failure management, follow-up testing, and support for symptoms and daily functioning.

How Attruby works in the body

Acoramidis is a transthyretin stabilizer. It binds to TTR and helps keep the protein in its normal, stable form. By stabilizing TTR, the medicine aims to reduce the dissociation step that can lead to formation of amyloid fibrils.

This mechanism is important because ATTR-CM is driven by ongoing production of unstable transthyretin protein. Attruby does not directly dissolve amyloid deposits that are already present. Instead, it is designed to slow the disease process by reducing the formation of additional amyloid fibrils.

Benefits and response are assessed over time rather than by how a person feels after the first few doses. Follow-up may include discussion of symptoms, physical examination, laboratory tests when clinically indicated, and cardiac assessments selected by the treating team.

Common and possible side effects

In clinical studies used for prescribing information, the most frequently reported adverse reactions with Attruby were diarrhea and upper abdominal pain. These effects may be mild for some people, but persistent digestive symptoms can affect hydration, nutrition, and adherence to treatment.

Patients should notify their prescribing clinician if diarrhea is severe, lasts several days, disrupts usual activities, or occurs with fever, vomiting, blood in the stool, marked weakness, or signs of dehydration. Abdominal pain that is intense, persistent, or worsening also needs medical review, since it may not be caused by the medication.

Changes in liver-related laboratory tests, including elevations in transaminases, have been reported. A clinician may assess liver health before or during treatment when appropriate, particularly in a person with known liver disease, symptoms of liver problems, or concerning test results.

Possible symptoms that deserve prompt assessment include yellowing of the eyes or skin, dark urine, unusually pale stools, persistent nausea or vomiting, itching, or pain in the upper right side of the abdomen. These symptoms do not always indicate a liver problem, but they should not be ignored.

• Diarrhea
• Upper abdominal pain
• Changes in liver blood tests

Interactions, precautions, and treatment planning

Before Attruby is started, patients should provide a complete list of prescription medicines, nonprescription medicines, vitamins, and herbal products. The official prescribing information describes potential interactions involving medicines transported by BCRP, including rosuvastatin, and medicines that are substrates of CYP2C9. A clinician or pharmacist can check the individual medicine list and determine whether monitoring or changes are needed.

Patients should also tell their clinician about liver disease, prior unexplained abnormal liver tests, pregnancy, plans for pregnancy, or breastfeeding. There may be limited information for some groups, and treatment decisions should balance the known benefit of managing ATTR-CM with individual circumstances.

Attruby can affect certain laboratory results. In particular, it may increase serum creatinine without a true reduction in kidney function in some patients. Clinicians interpret kidney tests alongside the person’s overall condition and, when needed, other markers of kidney function.

Questions about the prescribed schedule, missed doses, or whether Attruby can be taken with a particular medicine should be directed to the prescriber or pharmacist. Patients should follow the current official medication guide and prescribing instructions rather than changing the amount or timing themselves.

Using Attruby safely as part of heart care

ATTR-CM usually requires ongoing cardiovascular care. Attruby may be prescribed alongside other treatments that manage fluid retention, blood pressure, rhythm problems, or other features of heart failure. Each medicine has a different role, and changes to one treatment may affect the overall plan.

Keeping a brief symptom record can be useful. Patients may note changes in breathlessness, swelling, tiredness, weight, dizziness, bowel habits, and ability to complete usual activities. This information can help the care team distinguish a possible medication effect from progression of heart symptoms or an unrelated illness.

Healthy daily habits can support, but not replace, prescribed care. Depending on the clinician’s recommendations, these may include attending follow-up visits, taking medicines consistently, following guidance on sodium or fluid intake, remaining active within safe limits, and avoiding tobacco. Dietary or fluid restrictions should be individualized, especially for people using diuretics or living with kidney disease.

At Acibadem International, multidisciplinary specialists in JCI-accredited hospitals evaluate and treat cardiac conditions, including amyloidosis, for international patients. Coordinated care can include cardiology assessment, medication review, imaging, and support for longer-term follow-up.

When to seek medical care

Patients should contact their prescribing clinician soon for troublesome or persistent diarrhea, ongoing upper abdominal pain, new nausea or vomiting, or concerns about a possible medicine interaction. Early communication can often help address symptoms before they become more disruptive.

Urgent medical assessment is appropriate for signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat; trouble breathing; or widespread hives. Urgent care is also appropriate for possible significant liver symptoms, including yellow skin or eyes, very dark urine, severe or persistent abdominal pain, or repeated vomiting.

Because ATTR-CM affects the heart, emergency evaluation is needed for chest pain, fainting, severe shortness of breath, confusion, blue or gray lips, or rapidly worsening swelling. These symptoms may be related to heart disease or another urgent condition and should not be assumed to be an Attruby side effect.

Regular appointments remain important even when a person feels well. The care team can review tolerability, check for changes in health status, and coordinate treatment with the patient’s primary clinician, cardiologist, pharmacist, and other specialists as needed.

Frequently asked questions

What are the most common Attruby side effects?

The most commonly reported Attruby side effects are diarrhea and upper abdominal pain. Some patients may also have changes in liver blood-test results. Persistent, severe, or worsening symptoms should be discussed with the prescribing clinician.

What is Attruby used for?

Attruby is used in adults with transthyretin amyloid cardiomyopathy, also called ATTR-CM. It is approved to reduce cardiovascular death and cardiovascular-related hospitalizations. It is not intended for every type of amyloidosis.

How does Attruby work?

Attruby contains acoramidis, which stabilizes the transthyretin protein. Stabilizing this protein helps reduce the process that can lead to new amyloid fibril formation. It does not directly remove amyloid deposits already present in the heart.

Can Attruby affect liver tests?

Liver test changes, including increased transaminases, have been reported with Attruby. A clinician may consider liver assessment based on the patient’s health history, symptoms, and laboratory findings. Yellowing of the skin or eyes, dark urine, or persistent abdominal symptoms should be reported promptly.

Does Attruby interact with other medicines?

Yes, Attruby may interact with certain medicines, including some drugs transported by BCRP and medicines that are substrates of CYP2C9. Patients should give their clinician and pharmacist a full list of all medicines and supplements. They should not start or stop another medicine without professional advice.

Should a patient stop Attruby if diarrhea occurs?

A patient should not stop Attruby without speaking to the prescribing clinician. Mild diarrhea may be manageable, but severe, persistent, or dehydrating diarrhea needs timely medical advice. The clinician can assess possible causes and recommend the safest next step.

References

• U.S. Food and Drug Administration
• Attruby Prescribing Information
• American Heart Association
• National Institutes of Health
• Amyloidosis Research Consortium

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.